Sean Stevens

Sean Stevens has a diverse and extensive work experience spanning several industries. Sean is currently working as the Chief Science Officer (CSO) at KBio since April 2022. Prior to this, they served as the Vice President at Lung Biotechnology PBC from March 2018 to April 2022.

From 2014 to 2018, Sean worked at Synthetic Genomics, where they focused on mammalian synthetic biology. This company is dedicated to developing genomic-driven solutions and has key commercialization programs in synthetic DNA products, algae biofuels, and vaccine development.

Before that, they held the position of Vice President Research for Ablexis LLC from 2010 to 2014. This biotechnology company specializes in antibody drug discovery using the AlivaMab Mouse technology.

Sean also worked at AnaptysBio as a Director from 2009 to 2010. Prior to that, they had a significant tenure at Regeneron Pharmaceuticals, starting as a Scientist in 2000 and progressing to Senior Staff Scientist and Associate Director roles. Their responsibilities at Regeneron included technology evaluation, immunology research, collaboration coordination, and large-scale genomic modifications.

Sean began their career with summer internships at Picatinny Arsenal-Vehicle Fired Munitions from 1983 to 1986, gaining valuable experience early on.

In summary, Sean Stevens has held leadership roles in various biotechnology companies, specializing in areas such as synthetic biology, antibody drug discovery, and genomic-driven solutions.

Sean Stevens obtained their Bachelor of Science degree in Biology from Bucknell University between the years 1983 and 1987. Following this, they pursued a PhD in Molecular Biology at the University of Pennsylvania, completing their studies from 1987 to 1994.